Taken together, data from both preclinical and clinical studies provide strong evidence that IGF1R signaling is crucial for ACC growth and progression, and that the IGF2–IGF1R–MYB–NFIB axis is a key target for therapy in ACC. Here, NFIB is linked to adrenal cortex carcinoma.